RAPT Therapeutics, Inc. (RAPT) NASDAQ
58.01
+0.0000011(+0.00%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
58.01
+0.0000011(+0.00%)
Currency In USD
| Previous Close | 58.01 |
| Open | 58.01 |
| Day High | 58.01 |
| Day Low | 58.01 |
| 52-Week High | 58.02 |
| 52-Week Low | 5.67 |
| Volume | 10.85M |
| Average Volume | 2.34M |
| Market Cap | 959.26M |
| PE | -4.97 |
| EPS | -11.66 |
| Moving Average 50 Days | 49.05 |
| Moving Average 200 Days | 26.91 |
| Change | 0 |
Data not available
RAPT Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Jan 07, 2026 9:05 PM GMT
SOUTH SAN FRANCISCO, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients l
RAPT Therapeutics Initiates prestIgE Phase 2b Clinical Trial of Ozureprubart (RPT904) in Patients with Food Allergies
GlobeNewswire Inc.
Oct 27, 2025 12:00 PM GMT
Trial initiation in food allergy follows promising results in Phase 2 trial in chronic spontaneous urticaria, another IgE-driven conditionRAPT seeks to develop a differentiated anti-IgE therapy for the many patients with food allergies SOUTH SAN FRAN
RAPT Therapeutics Announces Pricing of Public Offering of Common Stock
GlobeNewswire Inc.
Oct 22, 2025 3:12 AM GMT
SOUTH SAN FRANCISCO, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT) (“RAPT”), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for p